How common is pancreatitis on Mounjaro?

The Mounjaro label reports 13 treated adults with confirmed acute pancreatitis in clinical studies. That equals 0.23 patients per 100 years of exposure, against 0.11 for comparison treatments. In the Zepbound weight reduction trials, 0.2% of patients had it on both the drug and placebo.

Does a high lipase result on Mounjaro mean I have pancreatitis?

Not by itself. The label reports average lipase rises of 31% to 42% in trials, in people without pancreatitis. It states that the clinical significance of these rises is unknown without other signs and symptoms of pancreatitis. Your clinician interprets the result together with your symptoms.

How is pancreatitis pain different from normal Mounjaro stomach upset?

NIDDK describes pancreatitis pain as starting in the upper abdomen, sometimes spreading to the back, and lasting for days. The label describes it as persistent or severe. Ordinary nausea on tirzepatide is common during dose increases and usually does not involve severe, lasting pain.

Is the pancreatitis risk the same for Zepbound?

Zepbound and Mounjaro contain the same drug, tirzepatide, and both labels carry the same acute pancreatitis warning. The Zepbound label adds trial counts for weight reduction and for obstructive sleep apnea. The instruction is the same: stop the drug if pancreatitis is suspected.

Can Mounjaro Cause Pancreatitis, and What Are the Warning Signs?

Q: Can I take Mounjaro if I had pancreatitis before?

The August 2026 label does not list past pancreatitis as a contraindication and gives no specific instruction for it. The Medication Guide tells patients to inform their healthcare provider if they have or have had problems with the pancreas. The decision depends on your history and belongs to your prescriber.

The short answer: Yes, it can, but trials suggest it is uncommon. The Mounjaro label reports 13 treated patients with confirmed acute pancreatitis in clinical studies, a rate of 0.23 per 100 years of exposure, against 0.11 for comparison treatments. Meta-analyses of randomized trials have not found a statistically significant rise in risk. The main warning sign is severe pain in the upper abdomen that does not go away and may spread to the back.

What do the Mounjaro and Zepbound labels say about pancreatitis?

The Mounjaro prescribing information (revised August 2026) lists acute pancreatitis in its Warnings and Precautions section. It says acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or Mounjaro.

The label gives numbers from clinical studies. Reviewers confirmed 14 events of acute pancreatitis in 13 Mounjaro-treated adults. That is 0.23 patients per 100 years of exposure. The comparison groups had 3 events in 3 patients, or 0.11 patients per 100 years of exposure.

The Zepbound prescribing information (revised August 2026) covers the same drug, tirzepatide, for weight management and obstructive sleep apnea. It carries the same warning and adds two more counts:

Weight reduction trials: 0.2% of Zepbound-treated patients had confirmed acute pancreatitis, against 0.2% on placebo. The exposure-adjusted rates were 0.14 and 0.15 patients per 100 years.
Sleep apnea trials: the rate was 0.84 patients per 100 years for Zepbound and 0 for placebo. These two trials included 467 patients in total, so the estimate rests on very few events.

Both labels also list acute pancreatitis among reactions reported after approval, including hemorrhagic and necrotizing pancreatitis that sometimes resulted in death. The labels state that these reports are voluntary, so no reliable frequency can be worked out from them.

What are the warning signs of pancreatitis?

According to NIDDK, the main symptom of acute pancreatitis is pain that begins slowly or suddenly in the upper abdomen. The pain can spread to the back, can be mild or severe, and can last several days. Other symptoms include fever, nausea and vomiting, a fast heartbeat, and a swollen or tender abdomen.

NIDDK says to seek care right away for these symptoms:

Pain or tenderness in the abdomen that is severe or becomes worse
Nausea and vomiting
Fever or chills
Fast heartbeat
Shortness of breath
A yellowish color of the skin or the whites of the eyes (jaundice)

The label wording is close to this. It describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting.

Nausea alone is a poor guide, because nausea is common on tirzepatide during dose increases. The feature that sets pancreatitis apart is the pain: severe, in the upper abdomen, and lasting. Our side effects guide covers the ordinary stomach symptoms.

What does the label say to do if pancreatitis is suspected?

The instruction to prescribers is short: if pancreatitis is suspected, discontinue the drug and start appropriate management. The patient Medication Guide says to stop using Mounjaro and call a healthcare provider right away for severe stomach-area pain that will not go away, with or without nausea or vomiting.

Doctors confirm the diagnosis with more than symptoms. NIDDK says blood tests look for high amylase and lipase levels, and imaging such as ultrasound or CT can show gallstones or pancreatitis itself.

The August 2026 labels do not say when, or whether, to restart tirzepatide after a confirmed case. That decision belongs to the treating clinician.

Do lipase and amylase rise on Mounjaro?

Lipase and amylase are digestive enzymes made in the pancreas. Both labels report that average levels go up on tirzepatide, even in people with no pancreatitis.

Mounjaro label: pancreatic amylase rose 33% to 38% from baseline and lipase rose 31% to 42%. On placebo, amylase rose 4% and lipase did not change.
Zepbound label: pancreatic amylase rose 20% to 25% and lipase rose 28% to 35%. On placebo, the rises were 2.1% and 5.8%.

Both labels state that the clinical significance of these elevations is unknown in the absence of other signs and symptoms of pancreatitis. The labels do not explain the cause of the rise. A raised lipase result with no pain is a different finding from pancreatitis.

What do meta-analyses and large studies show?

Randomized trials. A 2024 meta-analysis pooled 17 randomized trials with 14,645 participants. It found no statistically significant difference in confirmed pancreatitis between tirzepatide and placebo at any dose. The risk ratio for the 15 mg dose was 1.26 (95% CI 0.36 to 4.98). The same analysis confirmed larger rises in amylase and lipase than with placebo or insulin.

An earlier meta-analysis of nine trials and 9,871 participants reached a similar result (risk ratio 1.46, 95% CI 0.59 to 3.61). The confidence intervals in both analyses are wide. Pancreatitis events were too few to rule out a modest increase or a modest decrease.

Routine care. A 2026 cohort study funded by NIDDK compared adults with type 2 diabetes who started dulaglutide, semaglutide, or tirzepatide. Its combined outcome included acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation. The hazard ratio for tirzepatide against semaglutide was 1.07 (95% CI 0.90 to 1.26) across 46,620 matched pairs. This study compared the drugs with each other, not with no treatment.

A second cohort study matched 20,459 GLP-1 drug users with type 2 diabetes to 20,459 non-users. It did not find a higher risk of acute pancreatitis in the users. That study excluded pancreatitis caused by gallstones and alcohol, so it does not answer the gallstone question below.

Adverse event reports. An analysis of the FDA Adverse Event Reporting System found a reporting signal for acute pancreatitis with every GLP-1 drug it examined, tirzepatide included. A reporting signal shows that reports exist in higher proportion than expected. It cannot prove that the drug was the cause.

For the wider drug class, see glp1.md.

Who is at higher risk?

NIDDK names gallstones, heavy alcohol use, genetic disorders of the pancreas, and some medicines as the most common causes of pancreatitis. It also lists high levels of blood fats as a cause of chronic pancreatitis.

Gallstones. This cause matters most for people losing weight on tirzepatide. The Zepbound label warns about acute gallbladder disease and says acute gallbladder events were associated with weight reduction. Our post on Mounjaro and gallstones has the numbers.

High triglycerides. People with very high triglycerides have a separate reason to watch for symptoms. See Mounjaro, cholesterol, and triglycerides.

A past episode of pancreatitis. The August 2026 labels give no specific instruction for people with a prior history. The Medication Guide tells patients to inform their healthcare provider if they have or have had problems with the pancreas. One retrospective database study of people with past acute pancreatitis found fewer recurrences among GLP-1 drug users than non-users. That design cannot separate the drug's effect from differences between the groups, so it is not proof of safety.

The bottom line

Pancreatitis is a labeled risk of Mounjaro and Zepbound, and deaths have been reported after approval. In trials it was uncommon, and pooled trial data have not shown a statistically significant increase. The numbers are too small to settle the question. The practical point is the symptom: severe upper abdominal pain that does not go away, with or without vomiting, means stop the drug and get medical care right away.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Talk to your healthcare provider about your own pancreatitis risk before starting, stopping, or restarting tirzepatide.